In Silico Identification of Hydroxyxanthone Derivatives as CDK2/EGFR Dual Inhibitor for Colorectal Cancer Treatment

Key Points

• The study aims to identify hydroxyxanthone derivatives that can act as dual inhibitors of CDK2 and EGFR.
• Conducted in silico analysis to screen hydroxyxanthone derivatives
• Evaluated the inhibitory potential of X4, X5, and X7 against CDK2 and EGFR
• X4, X5, and X7 showed the strongest potential as dual CDK2/EGFR inhibitors
• These derivatives may serve as candidates for colorectal cancer treatment

Abstract